Glenmede Investment Management’s Corcept Therapeutics CORT Stock Holding History

Glenmede Investment Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$843K	Buy	+10,146	New	+$734K	﹤0.01%	752

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Glenmede Investment Management's CORT Position: Q3 2025 in Review

Glenmede Investment Management opened a new position in Corcept Therapeutics (CORT) in Q3 2025: 10,146 shares worth $843K. The stake represents ﹤0.01% of the portfolio and ranks #752 among its holdings.

429 funds tracked by Wall St. Rank hold CORT as of Q3 2025.

Glenmede Investment Management held 10,146 shares of Corcept Therapeutics worth $843K as of Q3 2025.
Corcept Therapeutics was a new Glenmede Investment Management position in Q3 2025.
Corcept Therapeutics made up ﹤0.01% of Glenmede Investment Management's portfolio in Q3 2025, its #752 holding.
429 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.